Proffitt & Goodson’s Novavax NVAX Stock Holding History

Proffitt & Goodson’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-18	Closed	-$131	–	228
2023 Q3	$131	Buy	+18	New	+$144	﹤0.01%	229

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Proffitt & Goodson's NVAX Position: Q4 2023 in Review

Proffitt & Goodson sold out of Novavax (NVAX) in Q4 2023, closing a stake of 18 shares — an estimated $131 sold.

Proffitt & Goodson first reported a position in NVAX in Q3 2023 and held it in 1 quarter. The position peaked at $131 in Q3 2023. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

Proffitt & Goodson reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
Proffitt & Goodson sold 18 Novavax shares in Q4 2023, an estimated $131.
Proffitt & Goodson first reported a position in Novavax in Q3 2023 and held it in 1 quarter.
Proffitt & Goodson's Novavax position peaked at $131 in Q3 2023.
199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Proffitt & Goodson's 13F filing for Q4 2023, filed 24 Jan 2024.